4597.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 09:15):

Stats
Dzisiejszy wolumen	954 300
Średni wolumen	3.29M
Kapitalizacja rynkowa	5.01B
EPS	¥0 ( 2024-02-14 )
Następna data zysków	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-3.93
ATR14	¥0.159 (0.61%)

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: -0.22 (neutral)

Signal:(48.14) Neutral

Solasia Pharma K.K. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Solasia Pharma K.K. Korelacja - Waluta/Towar

-0.08
( neutral )

0.15
( neutral )

0.31
( neutral )

0.16
( neutral )

-0.24
( neutral )

-0.09
( neutral )

Solasia Pharma K.K. Finanse

Annual	2023
Przychody:	¥617.00M
Zysk brutto:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2023
Przychody:	¥617.00M
Zysk brutto:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2022
Przychody:	¥1.09B
Zysk brutto:	¥662.00M (60.62 %)
EPS:	¥-16.76

FY	2021
Przychody:	¥559.00M
Zysk brutto:	¥374.00M (66.91 %)
EPS:	¥-19.04

Financial Reports:

No articles found.

Solasia Pharma K.K.

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.